SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Scheinin Annalotta)
 

Sökning: WFRF:(Scheinin Annalotta) > (2022) > Circulating oxylipi...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007695naa a2200493 4500
001oai:DiVA.org:his-23544
003SwePub
008240118s2022 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-235442 URI
0247 a https://doi.org/10.1016/j.bjao.2022.1001142 DOI
040 a (SwePub)his
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Nummela, Aleksiu Turku PET Centre, University of Turku and Turku University Hospital, Finland ; Department of Internal Medicine, Turku University Hospital, Finland4 aut
2451 0a Circulating oxylipin and bile acid profiles of dexmedetomidine, propofol, sevoflurane, and S-ketamine :b a randomised controlled trial using tandem mass spectrometry
264 1b Elsevier,c 2022
338 a electronic2 rdacarrier
500 a CC BY 4.0 DEEDCorresponding author: Aleksi Nummela, Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland. E-mail: aljunu@utu.fiFunding:Academy of Finland (266467 and 266434); Emil Aaltonen Foundation to LL; Finnish Medical Foundation, Eero Matti Raninen Fund to AN; Jane and Aatos Erkko Foundation; Orion Research Foundation to LL; The Paulo Foundation to LL; Signe and Ane Gyllenberg Foundation to KV; University of Turku Graduate School, University of Turku to AN.
520 a BackgroundThis exploratory study aimed to investigate whether dexmedetomidine, propofol, sevoflurane, and S-ketamine affect oxylipins and bile acids, which are functionally diverse molecules with possible connections to cellular bioenergetics, immune modulation, and organ protection.MethodsIn this randomised, open-label, controlled, parallel group, Phase IV clinical drug trial, healthy male subjects (n=160) received equipotent doses (EC50 for verbal command) of dexmedetomidine (1.5 ng ml−1; n=40), propofol (1.7 μg ml−1; n=40), sevoflurane (0.9% end-tidal; n=40), S-ketamine (0.75 μg ml−1; n=20), or placebo (n=20). Blood samples for tandem mass spectrometry were obtained at baseline, after study drug administration at 60 and 130 min from baseline; 40 metabolites were analysed.ResultsStatistically significant changes vs placebo were observed in 62.5%, 12.5%, 5.0%, and 2.5% of analytes in dexmedetomidine, propofol, sevoflurane, and S-ketamine groups, respectively. Data are presented as standard deviation score, 95% confidence interval, and P-value. Dexmedetomidine induced wide-ranging decreases in oxylipins and bile acids. Amongst others, 9,10-dihydroxyoctadecenoic acid (DiHOME) –1.19 (–1.6; –0.78), P<0.001 and 12,13-DiHOME –1.22 (–1.66; –0.77), P<0.001 were affected. Propofol elevated 9,10-DiHOME 2.29 (1.62; 2.96), P<0.001 and 12,13-DiHOME 2.13 (1.42; 2.84), P<0.001. Analytes were mostly unaffected by S-ketamine. Sevoflurane decreased tauroursodeoxycholic acid (TUDCA) –2.7 (–3.84; –1.55), P=0.015.ConclusionsDexmedetomidine-induced oxylipin alterations may be connected to pathways associated with organ protection. In contrast to dexmedetomidine, propofol emulsion elevated DiHOMEs, oxylipins associated with acute respiratory distress syndrome, and mitochondrial dysfunction in high concentrations. Further research is needed to establish the behaviour of DIHOMEs during prolonged propofol/dexmedetomidine infusions and to verify the sevoflurane-induced reduction in TUDCA, a suggested neuroprotective agent.Clinical trial registrationNCT02624401.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Anestesi och intensivvård0 (SwePub)302012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Anesthesiology and Intensive Care0 (SwePub)302012 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng
653 a Consciousness and Cognitive Neuroscience
653 a Kognitiv neurovetenskap och filosofi
7001 a Laaksonen, Lauriu Turku PET Centre, University of Turku and Turku University Hospital, Finland ; Department of Peri-operative Services, University of Turku and Turku University Hospital, Finland4 aut
7001 a Scheinin, Annalottau Turku PET Centre, University of Turku and Turku University Hospital, Finland ; Department of Peri-operative Services, University of Turku and Turku University Hospital, Finland4 aut
7001 a Kaisti, Kaikeu Turku PET Centre, University of Turku and Turku University Hospital, Finland ; Department of Peri-operative Services, University of Turku and Turku University Hospital, Finland4 aut
7001 a Vahlberg, Terou Department of Clinical Medicine, Biostatistics, Intensive Care and Pain Medicine, University of Turku and Turku University Hospital, Finland4 aut
7001 a Neuvonen, Mikkou Department of Clinical Pharmacology, University of Helsinki, Finland ; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Finland4 aut
7001 a Valli, Katja,d 1973-u Högskolan i Skövde,Institutionen för biovetenskap,Forskningsmiljön Systembiologi,Department of Peri-operative Services, University of Turku and Turku University Hospital, Finland ; Department of Psychology and Speech-Language Pathology, and Turku Brain and Mind Center, University of Turku, Finland,Kognitiv neurovetenskap och filosofi, Consciousness and Cognitive Neuroscience4 aut0 (Swepub:his)vala
7001 a Revonsuo, Anttiu Högskolan i Skövde,Institutionen för biovetenskap,Forskningsmiljön Systembiologi,Department of Psychology and Speech-Language Pathology, and Turku Brain and Mind Center, University of Turku, Finland,Kognitiv neurovetenskap och filosofi, Consciousness and Cognitive Neuroscience4 aut0 (Swepub:his)reva
7001 a Perola, Markusu Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Finland ; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Finland ; Finnish Institute for Health and Welfare, Helsinki, Finland4 aut
7001 a Niemi, Mikkou Department of Clinical Pharmacology, University of Helsinki, Finland ; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Finland ; Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Finland4 aut
7001 a Scheinin, Harryu Turku PET Centre, University of Turku and Turku University Hospital, Finland ; Department of Peri-operative Services, University of Turku and Turku University Hospital, Finland ; Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Finland4 aut
7001 a Laitio, Timou Department of Peri-operative Services, University of Turku and Turku University Hospital, Finland4 aut
7102 a Turku PET Centre, University of Turku and Turku University Hospital, Finland ; Department of Internal Medicine, Turku University Hospital, Finlandb Turku PET Centre, University of Turku and Turku University Hospital, Finland ; Department of Peri-operative Services, University of Turku and Turku University Hospital, Finland4 org
7730 t BJA Opend : Elsevierg 4q 4x 2772-6096
8564 u https://doi.org/10.1016/j.bjao.2022.100114y Fulltext
8564 u https://his.diva-portal.org/smash/get/diva2:1829168/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-23544
8564 8u https://doi.org/10.1016/j.bjao.2022.100114

Hitta via bibliotek

  • BJA Open (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy